Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes
Authors' conclusion
This ITC suggests that oral semaglutide 25 mg and s.c. semaglutide 2.4 mg offer comparable efficacy for weight management in adults with obesity.
Study context
- Population
- Adults with obesity or overweight with ≥ 1 weight-related complication, with similar lifestyle changes alongside semaglutide/placebo2 RCTs
- Comparison
- Oral semaglutide 25 mg vs s.c. semaglutide 2.4 mg
- Outcome
- Percentage change in body weight
Methodological detailsnaïve Bucher indirect treatment comparison (ITC), two randomized controlled trials (OASIS 4, STEP 1)
- Naïve Bucher ITC
- Two randomized controlled trials (OASIS 4, STEP 1)
Main finding
As reported in the abstract
s.c. semaglutide vs oral semaglutideETD, %-points (95% CI)
Treatment regimen estimand; small numerical advantage for s.c. semaglutide
1.01(−1.61 to 3.63)
Efficacy estimand; small numerical advantage for s.c. semaglutide
0.55(−2.25 to 3.35)
Further findings
All outcomes assessed (≥5%, ≥10%, ≥15%, ≥20% weight loss, cardiometabolic parameters, IWQoL-Lite-CT PF)
- Oral and s.c. semaglutide delivered comparable efficacy across all outcomes; differences and uncertainty supported therapeutic equivalence
Original publication
Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes. Diabetes Obes Metab. Published 1 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →